Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

T/R potency <5% [Regulatives / Guidelines]

posted by Achievwin – US, 2022-09-07 20:22 (153 d 03:29 ago) – Posting: # 23275
Views: 1,418

Colleagues:

Somewhere in the Bioequivalence guidance I remembered that when designing the studies we try to keep T/R potency +/-5%. Can someone point out where this kind of condition existed, (latest guidance has no mention of this)

Thanks in advance for your guidance,

Complete thread:

T/R potency <5%Achievwin 2022-09-07 18:22 [Regulatives / Guidelines]
- T/R potency <5% Helmut 2022-09-07 18:55
  - T/R potency <5% Achievwin 2022-09-07 20:50
    - T/R potency <5% jag009 2022-09-08 19:54
    - T/R potency <5% dshah 2022-09-09 10:48
      - T/R potency <5% Helmut 2022-09-09 12:13
      - T/R potency <5% Achievwin 2022-09-09 14:56
        
        T/R potency <5% Helmut 2022-09-09 17:08
        T/R potency <5% dshah 2022-09-09 17:42

Admin contact
22,485 posts in 4,710 threads, 1,603 registered users;
22 visitors (0 registered, 22 guests [including 15 identified bots]).
Forum time: 22:51 CET (Europe/Vienna)

The difference between a surrogate and a true endpoint
is like the difference between a cheque and cash.
You can get the cheque earlier but then,
of course, it might bounce. Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz